S
About
VantAI, operating under the Proxima brand, is a cutting-edge AI-driven drug discovery company whose mission is to decode and design the interfaces of life by making protein interactions fully programmable. The platform integrates three complementary, phase-shifting technologies centered on proximity modulator therapeutics—covering inducers, modulators, and blockers—to open a new chapter in medicine. At its core, VantAI leverages generative AI and deep learning to model protein structures, predict biomolecular interactions, and accelerate the discovery of next-generation therapeutics such as RIPTACs and other proximity-based medicines. The platform includes NEO-1, a flagship AI model designed for structural proteomics and drug interaction modeling. The company collaborates with leading industry partners and has forged high-value research alliances—including a $1B+ collaboration with Halda Therapeutics—demonstrating the platform's commercial and scientific credibility. VantAI also runs a monthly Generative AI in Drug Discovery lecture series, featuring contributions from NVIDIA, MIT, and Microsoft Research, making it a hub for frontier AI research in biomedicine. Primary users include pharmaceutical companies, biotech researchers, and computational biologists seeking to harness AI for proximity therapeutics, structural biology, and target identification. The platform is purpose-built for enterprise drug discovery teams working at the intersection of AI and life sciences.
Key Features
- Proximity Modulator Platform: Three integrated technologies targeting inducers, modulators, and blockers to make protein interactions fully programmable for therapeutic development.
- NEO-1 AI Model: A flagship generative AI model built for structural proteomics and biomolecular interaction modeling, enabling high-accuracy drug candidate identification.
- Generative AI for Drug Discovery: Leverages state-of-the-art generative deep learning to predict protein structures, model equilibrium ensembles, and design novel therapeutic molecules.
- Industry Collaboration Network: Partners with leading pharma and biotech companies, including a $1B+ research alliance with Halda Therapeutics for next-generation RIPTAC medicines.
- AI in Drug Discovery Lecture Series: Monthly educational series featuring frontier research from NVIDIA, MIT, and Microsoft Research on generative AI applications in drug discovery.
Use Cases
- Pharmaceutical companies using AI to identify and validate proximity modulator drug candidates, including molecular glues and PROTACs.
- Biotech research teams modeling protein-protein interaction interfaces to discover novel therapeutic targets.
- Computational biologists applying generative deep learning to predict 3D biomolecular structures and equilibrium ensembles.
- Drug discovery organizations partnering with Proxima to co-develop next-generation RIPTAC or degrader medicines through structured research alliances.
- Academic and industry researchers accessing the Generative AI in Drug Discovery lecture series to stay current with frontier AI methods in structural proteomics.
Pros
- Strong Scientific Credibility: Backed by $80M from DCVC and Nvidia, with an elite Scientific Advisory Board including Dr. Raymond Deshaies and other industry luminaries.
- Integrated Multi-Technology Platform: Combines generative AI, structural proteomics, and proximity therapeutics into a unified discovery engine rather than a single-point tool.
- High-Value Industry Partnerships: Proven traction with billion-dollar research collaborations, signaling real-world utility for enterprise pharmaceutical R&D.
Cons
- Enterprise-Only Access: The platform appears geared exclusively toward pharmaceutical companies and large biotech organizations, with no self-serve or individual researcher tier visible.
- Limited Public Documentation: Technical details, API access, and pricing information are not publicly disclosed, making independent evaluation difficult for new prospects.
Frequently Asked Questions
What is VantAI (Proxima) and what does it do?
VantAI, now operating as Proxima, is an AI drug discovery platform that uses generative AI and structural proteomics to make protein interactions programmable, enabling the development of proximity-based therapeutics such as molecular glues and RIPTACs.
What is NEO-1?
NEO-1 is Proxima's flagship AI model designed for structural proteomics and biomolecular interaction modeling, forming the core of its integrated drug discovery platform.
Who is VantAI designed for?
VantAI is built for pharmaceutical companies, biotech organizations, and computational biology teams seeking to leverage AI for proximity therapeutics discovery and protein interaction research.
How much funding has VantAI raised?
Proxima (VantAI) raised an $80 million seed round in January 2026, led by DCVC with participation from Nvidia and other investors.
What is the Generative AI in Drug Discovery lecture series?
It is a monthly educational series hosted by Proxima featuring leading researchers from institutions like NVIDIA, MIT, and Microsoft Research presenting frontier work on generative AI applications in drug discovery and structural biology.
